-Tenth Anniversary Celebration Series
-Approved the Establishment of Academicians and Experts Workstations
-Expansion of the New Laboratory Area with 10,000 square meters
-Expand Isotope Biomarker Services
-Passed the Review of CFDA GLP
-Successfully introduce new foreign drugs to domestic
-Establishment of new three party collaboration model:
Foreign Enterprise – Medicilon – Domestic
-Chinese government officially approve Shanghai
Medicilon Inc. become the holding company of
MPI Preclinical Research (Shanghai) LLC.
-Won “2013 China Top 10 the Most Investment
Value in CRO Industry”.
- Participate the filming of “DaDaoTongXing” as
the representative of Shanghai high-tech enterprises.
- Provide the complete application for both CFDA and
FDA IND filing.
- Three party collaboration to promote the drug
- Undertake the “Twelve Five Year Project” on
creating new drug task.
- GLP is successfully reviewed by both FDA and CFDA.
- China’s SFDA officially approved
Medicilon’s GLP Certification.
- Medicilon recognized as a “Cultivated
Little Giant Enterprise” in Shanghai’s high
- Fortune Capital signed investment
agreement with Medicilon aimed for
IPO in China.
- Medicilon is recognized as one of the
top seven integrated services CRO in
China in Citi Investment’s report.
- Medicilon "Shanghai isotope Drug
Metabolism professional and technical
services platform", selected the first
batch of ”Shanghai professional and
technical service platform”.
- Medicilon acquires international AAALAC Accreditation.
- Medicilon preclinical research facilities compliance
with US GLP standard.
- “Protein-crystallography-based Drug Discovery
and Screen Platform” of Medicilon was listed in
Shanghai R&D Public.
- “NHP Experimental Service Platform” of
Medicilon/MPI was listed in Shanghai R&D Public
- Medicilon established CMC platform.
- Animal facility in Medicilon approved by Shanghai
Animal Committee, was issued the License of
Laboratory Animal (Rat, Mouse, Dog and Monkey).
- The joint venture company, Medicilon Preclinical
Research, registered in Shanghai, begins to provide
preclinical GLP services.
- Laboratories expanded to 20,000 square meters
in the Chuansha campus which include the largest
animal facility (40 animal rooms) in Shanghai.
- Joint Venture agreement between Shanghai
Medicilon Inc. and MPI Research signed.
- Commenced non-GLP preclinical research and
- Moved into new facility and listed as one of
only 3 Chinese CROs in the top 30 CRO
companies in Outsourcing in Drug Discovery.
- Medicilon was acknowledged as Hi-tech
Enterprise by Shanghai Science Commission.
- Trademark “美迪西”(Medicilon Inc.) approved by Chinese
- Animal facilities were issued their respective licenses
(Rat, Mouse, Rabbit, Dog and Non-human primates).
- Established the first chemical synthesis FTE team.
- Medicilon registered in Shanghai,
Laboratory construction in
Zhangjiang Hi-tech Park.
- Initially provided Chemistry and
Bioanalysis Services .
- First LC/MC/MC was imported
for pharmacokinetics services.